Related references
Note: Only part of the references are listed.Gene therapy and DNA delivery systems
D. Ibraheem et al.
INTERNATIONAL JOURNAL OF PHARMACEUTICS (2014)
One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering
Haoyi Wang et al.
CELL (2013)
Live-attenuated bacteria as a cancer vaccine vector
Bertrand Toussaint et al.
EXPERT REVIEW OF VACCINES (2013)
Gene therapy clinical trials worldwide to 2012 an update
Samantha L. Ginn et al.
JOURNAL OF GENE MEDICINE (2013)
The State of Gene Therapies: The FDA Perspective
Daniel Takefman et al.
MOLECULAR THERAPY (2012)
Effect of Administration Route on the Biodistribution and Shedding of Replication-Deficient AAV2: A Qualitative Modelling Approach
Esther F.A. Brandon et al.
CURRENT GENE THERAPY (2010)
Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application
Aimee L. Jackson et al.
NATURE REVIEWS DRUG DISCOVERY (2010)
An inventory of shedding data from clinical gene therapy trials
Ellen A. M. Schenk-Braat et al.
JOURNAL OF GENE MEDICINE (2007)
siRNA therapeutics: Big potential from small RNAs
RCC Ryther et al.
GENE THERAPY (2005)
MicroRNAs: Genomics, biogenesis, mechanism, and function
DP Bartel
CELL (2004)
Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution
MW Konstan et al.
HUMAN GENE THERAPY (2004)
A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency
S Hacein-Bey-Abina et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Gene therapy progress and prospects: Nonviral vectors
T Niidome et al.
GENE THERAPY (2002)
Share Paper
